Abingdon Health is delighted to announce the appointment of Professor Lawrence S. Young PhD DSc FRSB FRCPath FRCP FMedSci as a scientific advisor to the company. Professor Young is internationally recognised for his work in virus infection and his initial focus with Abingdon Health will be to support the company’s work on developing tests for detection of antigens and antibodies to the SARS-CoV-2 virus.
Professor Young was appointed as a Pro-Vice Chancellor at the University of Warwick in January 2013 with responsibility for strategic planning and resources. In 2016 he became Vice-President at the University of Warwick, encompassing his existing responsibilities, while highlighting his leadership in the University’s engagement activities in China and Hong Kong. In 2018 Lawrence was appointed as Pro-Dean for External Affairs at Warwick Medical School and Director of the Warwick Cancer Research Centre. In 2019 Lawrence became co-lead of the new Warwick Health Global Research Priority. Before joining the University of Warwick he was Pro-Vice Chancellor and Head of the College of Medical and Dental Sciences at the University of Birmingham where he maintains an honorary Professorship in addition to other Professorships at Monash (Australia), Yat-sen (China) and Gadjah Mada (Indonesia) universities.
Lawrence is listed amongst the World’s most cited scientists in the ISI’s (Institute for Scientific Information) list of Highly Cited Researchers.
Dr Chris Hand, Chairman of Abingdon Health commented, “we are delighted that Lawrence has agreed to work with us as we proceed with various projects relating to SARS-CoV-2 and COVID-19. Lawrence’s expertise in virology and immunology will be particularly useful as we work on diagnostic tests for this virus particularly in relation to our work with the UK-RTC to develop a COVID-19 antibody test”.
Professor Young commented, “I look forward to working with the team at Abingdon Health. Their work with the UK-RTC will provide an invaluable tool for further understanding the effects of the SARS-CoV-2 infection on the UK population.”
Abingdon Health is a technology-enabled lateral flow diagnostics company providing innovative rapid testing solutions to a multi-industry, global client base. Located across 3 UK sites, Abingdon Health boasts specialist assay development and a Smartphone reader division alongside Europe’s largest lateral flow test manufacturing capacity. By combining a multi-disciplinary approach with precision automation Abingdon Health assures product consistency and security of supply for the most complex of assays and markets. Abingdon Health takes projects from initial concept through scale-up and into high-volume manufacturing in addition to accommodating clients looking to transfer their rapid test from third-party developers or manufacturers.
Abingdon Health is headquartered in York, United Kingdom. Visit www.abingdonhealth.com.